Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.
Identifieur interne : 001582 ( Main/Exploration ); précédent : 001581; suivant : 001583Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.
Auteurs : Jeanne M. Sisk [États-Unis] ; Matthew B. Frieman [États-Unis]Source :
- ACS infectious diseases [ 2373-8227 ] ; 2015.
Abstract
The current outbreaks of Middle East Respiratory Syndrome (MERS) and Ebolavirus (EboV) have revealed a gap in the development and availability of drugs to treat these infections. To date, there are no approved treatments for patients infected with MERS coronavirus (MERS-CoV), a virus that continues to infect new patients and that has now spread from the Middle East to Asia. Despite a downward trend in the number of new EboV cases in West Africa, new infections are still occurring, and many patients continue to suffer from this illness. People infected with MERS and Ebola viruses receive only supportive care in hopes of recovery. Investigation into repurposing drugs approved by the FDA is gaining interest. To identify better treatment strategies, several groups have used drug screens to repurpose FDA-approved drugs as inhibitors of MERS-CoV and EboV.
DOI: 10.1021/acsinfecdis.5b00089
PubMed: 27617922
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F69
- to stream PubMed, to step Curation: 000F69
- to stream PubMed, to step Checkpoint: 001354
- to stream Ncbi, to step Merge: 001777
- to stream Ncbi, to step Curation: 001777
- to stream Ncbi, to step Checkpoint: 001777
- to stream Main, to step Merge: 001587
- to stream Main, to step Curation: 001582
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.</title><author><name sortKey="Sisk, Jeanne M" sort="Sisk, Jeanne M" uniqKey="Sisk J" first="Jeanne M" last="Sisk">Jeanne M. Sisk</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:27617922</idno><idno type="pmid">27617922</idno><idno type="doi">10.1021/acsinfecdis.5b00089</idno><idno type="wicri:Area/PubMed/Corpus">000F69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F69</idno><idno type="wicri:Area/PubMed/Curation">000F69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F69</idno><idno type="wicri:Area/PubMed/Checkpoint">001354</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001354</idno><idno type="wicri:Area/Ncbi/Merge">001777</idno><idno type="wicri:Area/Ncbi/Curation">001777</idno><idno type="wicri:Area/Ncbi/Checkpoint">001777</idno><idno type="wicri:Area/Main/Merge">001587</idno><idno type="wicri:Area/Main/Curation">001582</idno><idno type="wicri:Area/Main/Exploration">001582</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.</title><author><name sortKey="Sisk, Jeanne M" sort="Sisk, Jeanne M" uniqKey="Sisk J" first="Jeanne M" last="Sisk">Jeanne M. Sisk</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:affiliation>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Maryland School of Medicine , Room 380, 685 West Baltimore Street, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author></analytic><series><title level="j">ACS infectious diseases</title><idno type="eISSN">2373-8227</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The current outbreaks of Middle East Respiratory Syndrome (MERS) and Ebolavirus (EboV) have revealed a gap in the development and availability of drugs to treat these infections. To date, there are no approved treatments for patients infected with MERS coronavirus (MERS-CoV), a virus that continues to infect new patients and that has now spread from the Middle East to Asia. Despite a downward trend in the number of new EboV cases in West Africa, new infections are still occurring, and many patients continue to suffer from this illness. People infected with MERS and Ebola viruses receive only supportive care in hopes of recovery. Investigation into repurposing drugs approved by the FDA is gaining interest. To identify better treatment strategies, several groups have used drug screens to repurpose FDA-approved drugs as inhibitors of MERS-CoV and EboV. </div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Sisk, Jeanne M" sort="Sisk, Jeanne M" uniqKey="Sisk J" first="Jeanne M" last="Sisk">Jeanne M. Sisk</name></noRegion><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001582 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001582 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27617922
|texte= Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27617922" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |